An economic evaluation on the pharmaceutical expenditure of antihypertensive agents in Taiwan from 1997 to 2002

Tong Lu Lin, Yea-Huei Kao, Chao Hsiun Tang, Huei Mei Wu, Hui Wen Cheng

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Antihypertensive medications have represented a tremendous financial burden to the health care plan globally. The utilization pattern of the antihypertensive agents was examined in this study to analyze the underlying reasons responsible for the pharmaceutical expenditure in Taiwan during 1997 to 2002. The claims data were obtained from National Health Insurance Research Database (NHIRD), which include ambulatory service record and prescription data of the entire population. Drug expenditure was decomposed into 5 components: relative drug price, number of patients treated, average physician visit per patient, defined daily dose (DDD) per physician visit and a residual. Total antihypertensive drug spending increased 102% during this period, mainly due to the compounding effect from the increment of patients treated (34%) and DDD per physician visit (33%). The aggregate residual for antihypertensive agents only exerts a 7% effect. Detailed residual analysis revealed that the brand-name product did have 11% increment, while the generic product had a 12% decrement. It also showed that hospital sector had a positive 11% residual, while primary care clinics had an 11% decrement. The most important factors that contribute to the expenditure surge of antihypertensive agents are the number of treated patients and DDD per physician visit. While physicians at the hospital sector adopted more new and innovative medications, their counterparts at the primary care clinics tended to switch some off-patent products to the generics.

Original languageEnglish
Pages (from-to)233-241
Number of pages9
JournalJournal of Food and Drug Analysis
Volume15
Issue number3
Publication statusPublished - 2007 Sep

Fingerprint

antihypertensive agents
Health Expenditures
economic analysis
Taiwan
physicians
Antihypertensive Agents
Cost-Benefit Analysis
Physicians
drugs
Pharmaceutical Preparations
drug therapy
brand name products
Primary Health Care
dosage
health insurance
National Health Programs
patents
health services
Names
Prescriptions

All Science Journal Classification (ASJC) codes

  • Food Science
  • Pharmacology

Cite this

Lin, Tong Lu ; Kao, Yea-Huei ; Tang, Chao Hsiun ; Wu, Huei Mei ; Cheng, Hui Wen. / An economic evaluation on the pharmaceutical expenditure of antihypertensive agents in Taiwan from 1997 to 2002. In: Journal of Food and Drug Analysis. 2007 ; Vol. 15, No. 3. pp. 233-241.
@article{991ab6f1669e478d9bce5adbbaa2ad61,
title = "An economic evaluation on the pharmaceutical expenditure of antihypertensive agents in Taiwan from 1997 to 2002",
abstract = "Antihypertensive medications have represented a tremendous financial burden to the health care plan globally. The utilization pattern of the antihypertensive agents was examined in this study to analyze the underlying reasons responsible for the pharmaceutical expenditure in Taiwan during 1997 to 2002. The claims data were obtained from National Health Insurance Research Database (NHIRD), which include ambulatory service record and prescription data of the entire population. Drug expenditure was decomposed into 5 components: relative drug price, number of patients treated, average physician visit per patient, defined daily dose (DDD) per physician visit and a residual. Total antihypertensive drug spending increased 102{\%} during this period, mainly due to the compounding effect from the increment of patients treated (34{\%}) and DDD per physician visit (33{\%}). The aggregate residual for antihypertensive agents only exerts a 7{\%} effect. Detailed residual analysis revealed that the brand-name product did have 11{\%} increment, while the generic product had a 12{\%} decrement. It also showed that hospital sector had a positive 11{\%} residual, while primary care clinics had an 11{\%} decrement. The most important factors that contribute to the expenditure surge of antihypertensive agents are the number of treated patients and DDD per physician visit. While physicians at the hospital sector adopted more new and innovative medications, their counterparts at the primary care clinics tended to switch some off-patent products to the generics.",
author = "Lin, {Tong Lu} and Yea-Huei Kao and Tang, {Chao Hsiun} and Wu, {Huei Mei} and Cheng, {Hui Wen}",
year = "2007",
month = "9",
language = "English",
volume = "15",
pages = "233--241",
journal = "Journal of Food and Drug Analysis",
issn = "1021-9498",
publisher = "National Laboratories of Foods and Drugs",
number = "3",

}

An economic evaluation on the pharmaceutical expenditure of antihypertensive agents in Taiwan from 1997 to 2002. / Lin, Tong Lu; Kao, Yea-Huei; Tang, Chao Hsiun; Wu, Huei Mei; Cheng, Hui Wen.

In: Journal of Food and Drug Analysis, Vol. 15, No. 3, 09.2007, p. 233-241.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An economic evaluation on the pharmaceutical expenditure of antihypertensive agents in Taiwan from 1997 to 2002

AU - Lin, Tong Lu

AU - Kao, Yea-Huei

AU - Tang, Chao Hsiun

AU - Wu, Huei Mei

AU - Cheng, Hui Wen

PY - 2007/9

Y1 - 2007/9

N2 - Antihypertensive medications have represented a tremendous financial burden to the health care plan globally. The utilization pattern of the antihypertensive agents was examined in this study to analyze the underlying reasons responsible for the pharmaceutical expenditure in Taiwan during 1997 to 2002. The claims data were obtained from National Health Insurance Research Database (NHIRD), which include ambulatory service record and prescription data of the entire population. Drug expenditure was decomposed into 5 components: relative drug price, number of patients treated, average physician visit per patient, defined daily dose (DDD) per physician visit and a residual. Total antihypertensive drug spending increased 102% during this period, mainly due to the compounding effect from the increment of patients treated (34%) and DDD per physician visit (33%). The aggregate residual for antihypertensive agents only exerts a 7% effect. Detailed residual analysis revealed that the brand-name product did have 11% increment, while the generic product had a 12% decrement. It also showed that hospital sector had a positive 11% residual, while primary care clinics had an 11% decrement. The most important factors that contribute to the expenditure surge of antihypertensive agents are the number of treated patients and DDD per physician visit. While physicians at the hospital sector adopted more new and innovative medications, their counterparts at the primary care clinics tended to switch some off-patent products to the generics.

AB - Antihypertensive medications have represented a tremendous financial burden to the health care plan globally. The utilization pattern of the antihypertensive agents was examined in this study to analyze the underlying reasons responsible for the pharmaceutical expenditure in Taiwan during 1997 to 2002. The claims data were obtained from National Health Insurance Research Database (NHIRD), which include ambulatory service record and prescription data of the entire population. Drug expenditure was decomposed into 5 components: relative drug price, number of patients treated, average physician visit per patient, defined daily dose (DDD) per physician visit and a residual. Total antihypertensive drug spending increased 102% during this period, mainly due to the compounding effect from the increment of patients treated (34%) and DDD per physician visit (33%). The aggregate residual for antihypertensive agents only exerts a 7% effect. Detailed residual analysis revealed that the brand-name product did have 11% increment, while the generic product had a 12% decrement. It also showed that hospital sector had a positive 11% residual, while primary care clinics had an 11% decrement. The most important factors that contribute to the expenditure surge of antihypertensive agents are the number of treated patients and DDD per physician visit. While physicians at the hospital sector adopted more new and innovative medications, their counterparts at the primary care clinics tended to switch some off-patent products to the generics.

UR - http://www.scopus.com/inward/record.url?scp=36448975519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36448975519&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 233

EP - 241

JO - Journal of Food and Drug Analysis

JF - Journal of Food and Drug Analysis

SN - 1021-9498

IS - 3

ER -